Project Grant R01CA305900
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $626K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Emigration Canyon, UT 84108, USA
Similar Awards
- Federal Project Grant Award Summary The University of Utah's Office of Sponsored Projects received a $634,900 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective April 1, 2026, through March 31, 2031. This five-year award funds preclinical and translational research investigating the combined effects of Focal Adhesion Kinase (FAK) inhibition with Mitogen-Activated Protein Kinase (MAPK) blockade as a therapeutic...
- Federal Grant Award Summary The University of Utah received a $635,581 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective June 1, 2026 through May 31, 2031. This five-year award supports the development of syngeneic, mutation-driven melanoma models in autoimmune-prone mice to advance understanding of immune checkpoint inhibitor (ICI) therapeutic efficacy and safety. The research addresses a critical gap in preclinical...
- Federal Project Grant Award Summary The University of Utah received a $518,090 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) beginning June 1, 2026 and extending through May 31, 2031. This five-year award supports fundamental research investigating the regulation of anti-tumor immunity by CX3CL1 (C-X3-C Motif Chemokine Ligand 1), a tumor-produced molecule that inhibits T cell-mediated cancer immunotherapy responses. The research...
- Federal Project Grant Award Summary The University of Utah received a $154,000 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective August 1, 2025, through July 31, 2027. This technology-oriented project will develop and validate a novel genetic mouse model system for pancreatic ductal adenocarcinoma (PDAC) research. The primary deliverable is the creation and functional validation of a "FLP-OUT" mouse model using a...
- Federal Project Grant Award Summary The University of Virginia received a $404,349 Project Grant from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) for the period April 1, 2026 through March 31, 2028. This award supports research to develop and validate an innovative magnetic resonance imaging (MRI) approach for quantifying drug delivery to brain tumors, specifically brain metastases in cancer patients. The project implements...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The University of Texas Southwestern Medical Center a $683,885 Project Grant under the Cancer Treatment Research program (CFDA 93.395) for the period of May 1, 2026 through April 30, 2031. This award supports the development of the first clinical prototype for Proton Minibeam Radiation Therapy (PMBRT), an advanced spatially fractionated radiation therapy modality designed to improve therapeutic outcomes in cancer...
- Federal Grant Award Summary The National Cancer Institute awarded a $700,838 Project Grant to The Regents of the University of California, San Francisco under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) for a five-year period beginning April 1, 2026. This award supports research to develop and optimize a Magnetic Resonance (MR) multi-tasking abdominal integrated imaging system (MT-AI2) capable of providing clinically accessible voxel-level liver functional assessment for...
- Federal Grant Award Summary Case Western Reserve University received a $630,108 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on March 13, 2026, with a completion date of February 28, 2030. The award supports the development and validation of a theranostic approach to breast cancer utilizing AKRO-6QC, a novel agent designed for fluorescence image-guided surgery (FIGS) combined with photothermal therapy (PTT). The research...
- Federal Grant Award Summary The National Cancer Institute awarded a $669,949 Project Grant (CFDA 93.396, Cancer Biology Research program) to the University of Utah, effective August 15, 2025, through July 31, 2030, to elucidate the functional role and therapeutic potential of G Protein-Coupled Receptor Kinase 2 (GRK2) in primary and therapy-resistant basal cell carcinoma (BCC). The research addresses a critical therapeutic gap in BCC treatment, where existing Smoothened (SMO) inhibitors lose...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $126,933 to the University of Utah under the Cancer Research Manpower program (CFDA 93.398) for a two-year project period commencing May 1, 2026. This Project Grant supports research training and career development in cancer research aligned with the National Cancer Program's strategic priorities. The award funds investigator-initiated research examining how androgens enhance immune responses to improve immunotherapy...